Form 4: Revolution Medicines Executive Stephen Michael Kelsey Acquires Shares and Options

Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, acquired 51,400 shares of common stock and 179,900 stock options on March 1, 2024.

Summary

• On March 1, 2024, Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, acquired 51,400 shares of common stock.
• These shares were acquired at a price of $0.
• Following the transaction, Kelsey directly owns 273,032 shares of Revolution Medicines common stock, including 110,413 restricted stock units.
• Kelsey also acquired 179,900 stock options with an exercise price of $29.80.
• The options vest monthly over four years from March 1, 2024.
• The options expire on February 28, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard Form 4 filing indicating insider transactions. The acquisition of shares and options could be interpreted as a positive sign, but it's not definitively bullish.

Positives

• The acquisition of shares and options by a key executive could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. Investors often monitor these filings for signals about management's confidence in the company's prospects.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence from a key executive.

Key Dates